JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

Coherus Biosciences Inc

Suletud

SektorTervishoid

1.01 -5.61

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.99

Max

1.07

Põhinäitajad

By Trading Economics

Sissetulek

-5.9M

-57M

Müük

-47M

7.6M

P/E

Sektori keskmine

2.432

40.048

Kasumimarginaal

-744.427

Töötajad

221

EBITDA

115K

-44M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+278.5% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

5.8M

124M

Eelmine avamishind

6.62

Eelmine sulgemishind

1.01

Uudiste sentiment

By Acuity

50%

50%

157 / 375 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Coherus Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. juuli 2025, 23:57 UTC

Omandamised, ülevõtmised, äriostud

EQT: To Spend Y407.82B for Tender Offer

29. juuli 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

EQT: Tender Offer Price Is Y5,700 a Share

29. juuli 2025, 23:54 UTC

Omandamised, ülevõtmised, äriostud

EQT To Start Tender Offer for Fujitec

29. juuli 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29. juuli 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29. juuli 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29. juuli 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29. juuli 2025, 22:44 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29. juuli 2025, 22:41 UTC

Omandamised, ülevõtmised, äriostud

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29. juuli 2025, 22:41 UTC

Omandamised, ülevõtmised, äriostud

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29. juuli 2025, 22:35 UTC

Tulu

IGO Maintains Nova Life of Mine Production Guidance

29. juuli 2025, 22:35 UTC

Tulu

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29. juuli 2025, 22:35 UTC

Tulu

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29. juuli 2025, 22:34 UTC

Tulu

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29. juuli 2025, 22:34 UTC

Tulu

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29. juuli 2025, 22:34 UTC

Market Talk
Tulu

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29. juuli 2025, 22:33 UTC

Tulu

IGO Had A$279.7 Million of Cash at End-June

29. juuli 2025, 22:33 UTC

Tulu

IGO 4Q Underlying Free Cash A$2.4 Million

29. juuli 2025, 22:33 UTC

Tulu

IGO FY Sales Revenue A$512.5 Million

29. juuli 2025, 22:33 UTC

Tulu

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29. juuli 2025, 22:32 UTC

Tulu

IGO FY Nickel Production 17,173 Tons

29. juuli 2025, 22:32 UTC

Tulu

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29. juuli 2025, 22:32 UTC

Tulu

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29. juuli 2025, 22:31 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

29. juuli 2025, 22:31 UTC

Market Talk
Tulu

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29. juuli 2025, 22:31 UTC

Tulu

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29. juuli 2025, 22:31 UTC

Tulu

IGO FY Spodumene Production 1.48 Million Tons

29. juuli 2025, 22:30 UTC

Tulu

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29. juuli 2025, 22:30 UTC

Tulu

IGO 4Q Underlying Ebitda A$62 Million

29. juuli 2025, 22:22 UTC

Tulu

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Võrdlus sarnastega

Hinnamuutus

Coherus Biosciences Inc Prognoos

Hinnasiht

By TipRanks

278.5% tõus

12 kuu keskmine prognoos

Keskmine 4.05 USD  278.5%

Kõrge 7 USD

Madal 1.1 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Coherus Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

3

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.9209 / 1.05Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

157 / 375 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.